How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 67.6 | 66.3 | 66.3 | 67.5 | 67.5 | 67.5 | -0.1 |
| Healthcare | 26.6 | 26.4 | 26.4 | 28.4 | 28.4 | 28.4 | +1.8 |
| Chemicals | 4.5 | 4.6 | 4.6 | 3.6 | 3.6 | 3.6 | -0.9 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 9.65% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 9.14% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| MAXHEALTH | Healthcare | 4.82% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| ASTERDM | Healthcare | 4.70% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| LUPIN | Pharma | 4.67% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| CIPLA | Pharma | 4.64% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| ALKEM | Pharma | 3.67% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| ACUTAAS | Chemicals | 3.58% | 5 | 10 | 3 | 8 | 2 | — | -8.5% |
| ANTHEM | Pharma | 3.56% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| NEULANDLAB | Healthcare | 3.40% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| IPCALAB | Pharma | 3.22% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| MEDANTA | Healthcare | 3.05% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| FORTIS | Healthcare | 2.79% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| KIMS | Healthcare | 2.70% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| GLENMARK | Pharma | 2.59% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| JLHL | Healthcare | 2.45% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
| TORNTPHARM | Pharma | 2.28% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| SHILPAMED | Pharma | 2.25% | 8 | 9 | 6 | 1 | 1 | — | +72.0% |
| VIJAYA | Pharma | 2.23% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| METROPOLIS | Pharma | 2.14% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| ZYDUSLIFE | Pharma | 2.10% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| BIOCON | Pharma | 2.01% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| DRREDDY | Pharma | 1.92% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| WOCKPHARMA | Pharma | 1.89% | 10 | 3 | 3 | 8 | 1 | Leader | +12.2% |
| SAILIFE | Healthcare | 1.62% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| RUBICON | Pharma | 1.61% | 7 | 8 | 5 | 4 | 1 | — | +43.6% |
| APOLLOHOSP | Healthcare | 1.58% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| THYROCARE | Pharma | 1.42% | 7 | 10 | 8 | 9 | 2 | — | +1.4% |
| AJANTPHARM | Pharma | 1.28% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| ERIS | Pharma | 1.25% | 3 | 8 | 4 | 9 | 8 | — | -7.4% |
| CORONA | Pharma | 1.24% | 5 | 9 | 7 | 2 | 1 | — | +14.6% |
| GLAND | Pharma | 1.07% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| JUBLPHARMA | Pharma | 1.01% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
| BAJAJHCARE | Pharma | 0.65% | 2 | 2 | 4 | 9 | 10 | — | +8.7% |
| NOVARTIND | Healthcare | 0.51% | 9 | — | — | 7 | 1 | Leader | +16.9% |
| COHANCE | Healthcare | 0.36% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
Performance · 2.9y
Over the last 2.9 years ₹100 in the fund grew to ₹220 (+120%), vs ₹135 for Nifty 500 (+35%) and ₹122 for Nifty 50 (+22%). Its relative-strength line ended at 180 vs Nifty 50 and 163 vs Nifty 500 — above 100, sustained outperformance.